Parkinson’s Disease and Latent (Hidden) Viruses: CBCD Reports an Important Discovery on the Cause of the Disease

January 15, 2021

Parkinson’s Disease and latent (hidden viruses) study: The cause of most Parkinson’s disease cases is unknown. However, it is well documented that mitochondrial dysfunction and misfolded α synuclein aggregation are important cellular abnormalities associated with the disease.

In this paper, we use the microcompetition model to show how latent viruses, which infect the central and peripheral nervous systems, can cause the observed mitochondrial dysfunction and excess α synuclein aggregation, and eventually, Parkinson’s disease. View study here published in the Journal of NeuroVirology.

The discovery was made possible by using the microcompetition model.  The model uncovered new relationships between seemingly unrelated observations reported in the scientific literature.  The discovery describes the molecular steps that lead from a latent infection to the clinical symptoms of Parkinson’s disease.  Many common viruses can cause the disease. They include the Epstein-Barr virus (EBV), Cytomegalovirus (CMV), Herpes Simplex Virus 1 (HSV-1), and Varicella Zoster Virus (VZV).

The model shows that an increase in the concentration of these viruses, or copy number, during the latent phase, increases the risk of developing Parkinson’s disease.  What can increase this viral copy number? A damaged immune system.  Events that decrease the efficiency of the immune system include aging, certain medications, surgery, chemotherapy, radiation, stress, and more.

The microcompetition model was used to discover the effects of latent viruses on other diseases too. It was used to show how latent viruses can cause breast cancer (2), and other cancers (3).  The model was created by Hanan Polansky, and was introduced in his book: “Microcompetition with Foreign DNA and the Origin of Chronic Disease.”

For jobs in medicine click here.


References

(1)  Polansky H, Lori G. How microcompetition with latent viruses can cause α synuclein aggregation, mitochondrial dysfunction, and eventually Parkinson’s disease. J Neurovirol. 2021 Jan 6. doi: 10.1007/s13365-020-00929-x

(2)  Polansky H, Schwab H. How latent viruses cause breast cancer: An explanation based on the microcompetition model. Bosn J Basic Med Sci. 2019 Aug 20;19(3):221-226. doi: 10.17305/bjbms.2018.3950.

(3)  Polansky H, Schwab H. Copy number of latent viruses, oncogenicity, and the microcompetition model. Oncotarget. 2018 Aug 3;9(60):31568-31569. doi: 10.18632/oncotarget.25804. eCollection 2018 Aug 3.

Hot this week

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution